Retinitis Pigmentosa (RP) covers a family of inherited retinal disorders in which the rod and cone photoreceptors degenerate progressively. Most patients notice difficulty seeing in dim light first, followed by a gradual narrowing of peripheral vision, with central vision affected later in the course. Dozens of different genes can be responsible, and for the great majority of subtypes there is no treatment that halts or reverses the process. Standard care therefore rests on accurate diagnosis, genetic counselling for the wider family, and low-vision rehabilitation. Patients from Pakistan often come to India for retinal imaging and genetic assessment, and to discuss whether stem cell therapy has anything to offer in their particular case.
Genetic testing for inherited retinal disease is not widely available in Pakistan, and many patients live for years with a clinical diagnosis but no confirmed subtype — which matters, because prognosis and any future trial eligibility depend on it. Consanguineous marriage patterns also mean several members of one family may be affected, making genetic counselling particularly valuable. Coming to India allows patients to obtain ERG and OCT testing, discuss the genetic picture, and get a clear answer on whether regenerative options are relevant, all within one visit.
Dr. Tyagi leads regenerative medicine protocol design at Stem Cell Cure India, overseeing stem cell sourcing, lab processing, and treatment planning for patients being evaluated for retinal and other regenerative conditions.
Dr. Pallavee contributes more than two and a half decades of ophthalmic surgical and clinical experience, and leads the retinal and ophthalmological assessment for patients travelling from Pakistan with retinitis pigmentosa.
Mesenchymal Stem Cells (MSCs) are being researched for neuroprotective and anti-inflammatory properties and for whether they might help surviving photoreceptors remain viable for longer in some retinal degenerations. Two points need to be understood before anyone travels: stem cell therapy does not alter the faulty gene that causes inherited RP, and it is not established as a way of recovering sight that has already gone. Whatever is discussed after an evaluation is positioned as an addition to — not a substitute for — genetic counselling, low-vision rehabilitation and regular review by a retina specialist.
The genetic subtype, how far the degeneration has progressed, and the amount of usable vision remaining all influence the answer. Before travel from Pakistan, our team reviews:
No. RP is caused by a genetic fault, and stem cell therapy does not correct that fault. It is discussed only as a possible support for remaining retinal function alongside genetic counselling and low-vision care, and it is not a cure.
Yes. Genetic testing is helpful but not a precondition for an initial opinion. Send your ERG, visual field and OCT results along with the family history, and our team will advise whether genetic testing should be arranged during your visit.
A strong family history is useful information and is taken into account during assessment. It also makes genetic counselling more valuable, since it can inform relatives who are not yet symptomatic.
ERG results, a visual field test, a recent retinal OCT scan, and a genetic report if one exists. A written account of how your night vision changed over time is also helpful.
Most patients plan for 7 to 10 days, which allows time for retinal testing here and for the treatment plan to be discussed properly.
Cost depends on the subtype, the stage of disease and the plan proposed. Send your reports and a personalised quote will be prepared for you.
Source: These are real, verified Google reviews currently published on stemcellcure.in — pulled from our Google Business Profile (5.0★, 33+ reviews).
Send us your ERG, visual field and OCT reports, and our team will give you a clear opinion on whether an evaluation is worthwhile in your case.
